

|                                  |                                      |                            |                    |
|----------------------------------|--------------------------------------|----------------------------|--------------------|
| <b>Patient Name</b>              | : Mr. BRIAN SSEMUGOOMA               | <b>Sample UID No.</b>      | : 4111619          |
| <b>Age / Gender</b>              | : 29 Y / Male                        | <b>Sample Collected On</b> | : 23-08-2025 09:45 |
| <b>Patient ID</b>                | : QLD111070                          | <b>Registered On</b>       | : 23-08-2025 11:51 |
| <b>Referred By</b>               | : DR FARHAN                          | <b>Reported on</b>         | : 23-08-2025 18:38 |
| <b>Referral Client</b>           | : CITICARE MEDICAL CENTER(INSURANCE) | <b>External Patient ID</b> | : 47690            |
| <b>Emirates ID / Passport No</b> | :                                    | <b>Print Version</b>       | : V.1              |

### Department of BIOCHEMISTRY

| <b>Investigation</b>       | <b>Results</b> | <b>Flag</b> | <b>Units</b> | <b>Biological Reference Interval</b> | <b>Method</b>                               |
|----------------------------|----------------|-------------|--------------|--------------------------------------|---------------------------------------------|
| * C-REACTIVE PROTEIN (CRP) | <b>13.2</b>    | <b>H</b>    | mg/L         | < 5                                  | Particle enhanced immunoturbidimetric assay |

Sample: Serum

**Comments :**

#### CLINICAL IMPLICATIONS:

1. CRP is the most sensitive acute phase reactant that can increase dramatically (100-fold or more) after severe trauma, bacterial infection, inflammation, surgery or neoplastic proliferation. CRP levels may predict future cardiovascular events and can be used as a screening tool.
2. The traditional test of CRP has added significance over the elevated ESR, which may be influenced by altered physiologic states. CRP tends to increase before rises in antibody titres and ESR level occurs. CRP levels also tend to decrease sooner than ESR levels.
3. The traditional test for CRP is elevated in rheumatic fever, RA, myocardial infarction, malignancy, bacterial and viral infections. The positive test indicates active inflammation but not its cause. In RA, the traditional test for CRP becomes negative with successful treatment and indicates that the inflammation has subsided.
4. High sensitive measurement of CRP (hs-CRP) are useful in assessing vascular inflammation and cardiovascular stratification. A single test for hs-CRP may not reflect an individual patient basal hs-CRP level, therefore follow up tests or serial measurements may be required in patients presenting with increased hs-CRP levels.


**INTERFERING FACTORS:** Haemolysed or lipemic sample may alter the results.

#### REFERENCE:

- 1) Manual of Laboratory and Diagnostics -Frances Fischbach Marshall B. Dunning III [9th Edition]
- 2) Tietz clinical guide to Laboratory tests(Fourth edition) ALAN H.B.WU

#### **Note:**

"The analytes with asterisk (\*) symbol are non-accredited parameters."  
"QLabs compliance with ISO 15189:2022 standards"



**Vaishnav Jayamohan**  
Lab Technologist

DHA No. 87250933-002





**Dr. Vidhya Mohan**  
Specialist Clinical Pathologist  
Clinical Pathologist  
DHA No. 23553203-004



**Dr. Dheepa Manoharan**  
Medical Director  
Specialist Microbiologist  
DHA No. 00231751-004

|                                  |                                      |                            |                    |
|----------------------------------|--------------------------------------|----------------------------|--------------------|
| <b>Patient Name</b>              | : Mr. BRIAN SSEMUGOOMA               | <b>Sample UID No.</b>      | : EB4111619        |
| <b>Age / Gender</b>              | : 29 Y / Male                        | <b>Sample Collected On</b> | : 23-08-2025 09:45 |
| <b>Patient ID</b>                | : QLD111070                          | <b>Registered On</b>       | : 23-08-2025 11:51 |
| <b>Referred By</b>               | : DR FARHAN                          | <b>Reported on</b>         | : 23-08-2025 18:38 |
| <b>Referral Client</b>           | : CITICARE MEDICAL CENTER(INSURANCE) | <b>External Patient ID</b> | : 47690            |
| <b>Emirates ID / Passport No</b> | :                                    | <b>Print Version</b>       | : V.1              |

### Department of HEMATOLOGY

#### COMPREHENSIVE COMPLETE BLOOD COUNT

| <u>Investigation</u>             | <u>Results</u> | <u>Flag</u> | <u>Units</u>        | <u>Biological Reference Interval</u> | <u>Method</u>        |
|----------------------------------|----------------|-------------|---------------------|--------------------------------------|----------------------|
| HEMOGLOBIN                       | 14.6           |             | g/dl                | 13-17                                | photometric          |
| RBC COUNT                        | 4.57           |             | 10 <sup>6</sup> /uL | 4.5-5.5                              | Electrical Impedance |
| HEMATOCRIT                       | 43.2           |             | %                   | 42-52                                | Calculation          |
| MCV                              | 94.5           |             | fL                  | 78-100                               | Calculation          |
| MCH                              | 32             | H           | pg                  | 27-31                                | Calculation          |
| MCHC                             | 33.9           |             | g/dl                | 31-35                                | Calculation          |
| RDW                              | 13.5           |             | %                   | 9.3-16                               | Calculation          |
| RDW-SD                           | 45.9           |             | fL                  | 38.9-49                              | Calculation          |
| MPV                              | 7.9            | L           | fL                  | 8.8-12.5                             | Calculation          |
| PLATELET COUNT                   | 217            |             | 10 <sup>3</sup> /uL | 150-400                              | Electrical Impedance |
| * PCT                            | 0.2            |             | %                   | 0.01-9.99                            | Calculation          |
| * PDW                            | 16             |             |                     | 0.1-99.9                             | Calculation          |
| * NUCLEATED RBC (NRBC)^          | 0.2            |             | /100 WBC            |                                      | Flow Cytometry       |
| * ABSOLUTE NRBC COUNT^           | 0.01           |             | 10 <sup>3</sup> /uL |                                      | Calculation          |
| * EARLY GRANULOCYTE COUNT (EGC)^ | 0.17           |             | %                   |                                      | Flow Cytometry       |
| * ABSOLUTE EGC^                  | 0.01           |             | 10 <sup>3</sup> /uL |                                      | Calculation          |
| WBC COUNT                        | 7              |             | 10 <sup>3</sup> /uL | 4-11                                 | Electrical Impedance |
| * Neutrophil                     | 75.17          |             | %                   | 40-80                                | VCS-Method           |
| * Lymphocyte                     | 12.18          | L           | %                   | 20-40                                | VCS-Method           |
| * Eosinophil                     | 3.44           |             | %                   | 1-8                                  | VCS-Method           |
| * Monocyte                       | 8.22           |             | %                   | 2-10                                 | VCS-Method           |
| * Basophil                       | 0.99           |             | %                   | 0-2                                  | VCS-Method           |
| * ABSOLUTE NEUTROPHIL COUNT      | 5.3            |             | 10 <sup>3</sup> /uL | 1.5-7                                | Calculation          |
| * ABSOLUTE LYMPHOCYTE COUNT      | 0.86           | L           | 10 <sup>3</sup> /uL | 1.5-4                                | Calculation          |
| * ABSOLUTE MONOCYTE COUNT        | 0.58           |             | 10 <sup>3</sup> /uL | 0-0.8                                | Calculation          |
| * ABSOLUTE EOSINOPHIL COUNT      | 0.24           |             | 10 <sup>3</sup> /uL | 0-0.6                                | Calculation          |
| * ABSOLUTE BASOPHIL COUNT        | 0.07           |             | 10 <sup>3</sup> /uL | 0-0.2                                | Calculation          |


Sample: EDTA Whole Blood

- END OF REPORT -

**Note:**

"The analytes with asterisk (\*) symbol are non-accredited parameters."

"QLabs compliance with ISO 15189:2022 standards"



Vaishnav Jayamohan  
Lab Technologist

DHA No. 87250933-002





Dr. Vidhya Mohan  
Specialist Clinical Pathologist  
Clinical Pathologist

DHA No. 23553203-004